Kamada Announces Two Abstracts on Alpha-1 Antitrypsin Accepted for Presentation at the International Conference of the American Thoracic Society
NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, today announced that two abstracts on the Company’s proprietary lead clinical candidate, Alpha-1 Antitrypsin (AAT), will be presented at the International Conference of the American Thoracic Society, May 15-20 in San Diego, California.
The presentations are as follows:
- Poster Presentation entitled “Safety and Efficacy of Inhaled Human Alpha-1 Antitrypsin (AAT) in Cystic Fibrosis (CF): A Report of a Phase II Clinical Study” to be presented Sunday, May 17 between 8:15 AM and 9:15 AM PT in Ballroom B of the San Diego Marriott Hotel and Marina. A poster discussion with Prof. Eitan Kerem, Professor of Pediatrics, Head, Department of Pediatrics, Hadassah Medical Center, Mt. Scopus, Jerusalem, will take place immediately following the poster presentation.
- Poster Presentation entitled "Phase II/III Randomized Double-Blind Comparison of Alpha-1 Antitrypsin (Kamada-AAT) with Active Comparator in Alpha-1 Antitrypsin Deficient Subjects" to be presented Monday, May 18 between 8:15 AM and 9:15 AM PT in Area G (Sails Pavilion, Upper Level) between 8:15 -16:00. Poster will be presented by Robert Sandhaus, MD, PhD, FCCP, Professor of Medicine Director, Alpha-1 Program, National Jewish Health, Denver Co.
About IV AAT
Kamada has developed a unique, high purity, liquid, ready-to-use human plasma derived AAT indicated for the treatment of hereditary Alpha 1 Deficiency. The product that is produced using sophisticated, chromatographic purification methods, has successfully completed the US pivotal trial during 2008, as presented in the poster above.
About Inhaled AAT
Kamada’s second generation AAT product to be administered via inhalation, is a high purity Alpha-1 Antitrypsin preparation that utilizes an optimized Investigational eFlow Nebulizer System (PARI Pharma GmbH). The product has been designated as an Orphan Drug for the treatment of Alpha-1 Deficiency, Bronchiectasis, and Cystic Fibrosis, in the U.S as well as for Alpha-1 Deficiency and Cystic Fibrosis in Europe. This designation grants Kamada various benefits such as research fund support, tax incentives, reduced official fees and seven years of exclusive distribution rights, if the company’s product is first on the market.
About Kamada
Kamada is a public biopharmaceutical company (TASE:KMDA) developing, producing and marketing a line of specialty life-saving biopharmaceuticals. Licensed and marketed worldwide, several of these specialty therapeutics are currently undergoing advanced clinical trials. Additional information is available at www.kamada.com
Contacts
Kamada
Mrs. Pnina Strauss, +972 8-940 6472
Clinical Development Manager
No comments:
Post a Comment